(SeaPRwire) –   PHOENIXVILLE, Pa., March 30, 2026 — PleoPharma, Inc., a privately held firm dedicated to discovering treatments for health issues related to cannabis, announced today that its leadership will deliver a presentation at the Centri Capital Conference in New York City on April 14, 2026, at 8:30 a.m. Eastern Time (ET).

About PleoPharma, Inc.
PleoPharma, Inc. is a clinical-stage development company operating in the neuropsychology and addiction sector, focused on identifying solutions for individuals grappling with cannabis addiction and other cannabis-related health conditions. PleoPharma’s primary asset, PP-01, is progressing into Phase 3 clinical trials and is being developed as the first FDA-approved treatment for Cannabis Withdrawal Syndrome in patients diagnosed with Cannabis Use Disorder.

The U.S. Government reported that in 2024 (samhsa.gov), approximately 20 million Americans experienced Cannabis Use Disorder. The number of individuals who sought treatment for cannabis-related health problems increased by an average of 28% annually from 2018 to 2023.

The PleoPharma team comprises a world-class management team and board of directors who have collectively achieved multiple high-value exits, over 50 worldwide product approvals, and more than 100 Investigational New Drug (IND) applications. PleoPharma concluded a Series B financing round, raising $36 million, in the fall of 2025, and has secured over $60 million since its establishment in 2019.

For additional details on PleoPharma Inc., please visit www.PleoPharma.com or contact Jason Goodson, Chief Business Officer, via email at jgoodson@pleopharma.com.

This release contains ‘forward-looking statements’ concerning the operations of PleoPharma, Inc. Actual results may diverge from its expectations, estimates, and projections, and consequently, these forward-looking statements should not be relied upon as forecasts of future events. All statements herein, other than those of historical facts, are forward-looking statements that reflect the current beliefs and expectations of PleoPharma’s management. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. PleoPharma does not assume or accept any obligation or undertaking to issue any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances upon which any such statement is based.

SOURCE PleoPharma, Inc